Roche (RHHBY) said it shared real-world evidence from the rollout of Accu-Chek SmartGuide continuous glucose monitoring solution at the European Association for the Study of Diabetes annual meeting on Tuesday, and announced its integration with the mySugr diabetes management app. “The Accu-Chek SmartGuide CGM solution is a significant step towards providing greater peace of mind for people living with diabetes, due to the AI-enabled predictive capabilities it offers. This empowers patients to take action before undesired events occur,” said Rodrigo Diaz de Vivar, Lifecycle Leader Patient Insights, Roche Diagnostics.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots
- Advertising, drugmaker stocks in spotlight as Trump moves to regulate pharma ads
- Omnicom, WPP under pressure after Trump moves to regulate pharma ads
- Trump Trade: U.S. President signs new pharma order
- Trump signs memorandum mandating pharma ads give more info on risks